Cytogam
Blood & Organ Banks · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
221 River St, Hoboken, New Jersey, 07030...Phone Number
+972 89406472Website
www.cytogam.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Cytogam
Kamada Inc. is a global biopharmaceutical company specializing in innovative hyperimmune therapies, particularly in the field of transplantation and infectious diseases. Their flagship product, CYTOGAM, is an intravenous immunoglobulin designed to provide additional cytomegalovirus (CMV) protection for high-risk solid organ transplant patients. The company aims to address high unmet medical needs by offering specialty plasma therapies that deliver passive immunity against various infectious agents. Kamada is dedicated to advancing human health and improving patient outcomes through their specialized treatments.Explore more
Popular SearchesCytogamSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cytogam your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Cytogam has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Cytogam has new funding data
Earning: See what the market has to say on Cytogam recently announced quarterly report
Check out if Cytogam is spiking on competitors!
Cytogam, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Cytogam
Product Launch: Get notified when Cytogam launches new products
Click to see if Cytogam had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Cytogam
Find 2 more new buyers
Compare Similar Companies to Cytogam
Compare insights from companies similar to Cytogam, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Cytogam
<$5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Cytogam is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Cytogam is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Cytogam.
Cytogam Tech Stack
A closer look at the technologies used by Cytogam
Cytogam News & Media
Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® at the Company’s Facility in Israel
REHOVOT, Israel and HOBOKEN, N.J. , Jan. 04, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) to manufacture CYTOGAM® (Cytomegalovirus Immune Globulin Intravenous [Human]) (CMV-IGIV) at its facility in Beit Kama, Israel. The application was submitted as a prior approval su
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cytogam
Sign Up For FreeTo access detailed company insights
Kamada Inc. is a global biopharmaceutical company specializing in innovative hyperimmune therapies, particularly in the field of transplantation and infectious diseases. Their flagship product, CYTOGAM, is an intravenous immunoglobulin designed to provide additional cytomegalovirus (CMV) protection for high-risk solid organ transplant patients. The... Read More
